COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

TAK-700 in Castration Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01658527
Recruitment Status : Withdrawn (Pharmaceutical company has terminated orteronel (TAK-700) development for Prostate Cancer)
First Posted : August 7, 2012
Last Update Posted : June 10, 2016
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary:
The objective of this randomized phase II open label trial is to determine the anti-tumor activity of TAK-700 (Orteronel) as compared to bicalutamide in terms of clinical progression-free survival in prostate cancer patients who failed 1st line treatment with LHRH (luteinizing hormone-releasing hormone) agonists or surgical castration.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Orteronel Drug: Bicalutamide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Randomized Comparative Trial of TAK-700 (Orteronel) Versus Bicalutamide in Metastatic Prostate Cancer Patients Failing 1st Line Treatment With LHRH Agonists or Surgical Castration.
Study Start Date : January 2014
Estimated Primary Completion Date : January 2016
Estimated Study Completion Date : January 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Orteronel, 300 mg twice daily Drug: Orteronel

Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.

Upon progression, patient may stay on study medication until the initiation of a new therapy

Other Name: TAK 700

Active Comparator: Bicalutamide 50 mg per day Drug: Bicalutamide
Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.

Primary Outcome Measures :
  1. The primary endpoint of the trial is clinical progression free survival.
    The primary endpoint of the trial is clinical progression free survival. In this protocol, it is defined according to the recommendations of the "Prostate-Cancer clinical trials Working Group 2" and referred to as the "PCWG2" for the setting "delay/prevent" progression.

Secondary Outcome Measures :
  1. RECIST (Response Evaluation Criteria In Solid Tumors) response in patients presenting with measurable disease
  2. Time to PSA (Prostate specific antigen) progression and PSA change from baseline
  3. Overall survival
  4. Safety according to Common Terminology Criteria for Adverse Events, version 4.03
  5. Pain (when an SAE (Serious Adverse Event)) or pain requiring initiation of narcotic analgesia
  6. Skeletal related events, including requirement to initiate chemotherapy, radiotherapy, cord compression or requirement for surgery to the bone

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Histologically confirmed diagnosis of prostate adenocarcinoma
  • Metastatic disease in bone or other lesions documented by imaging. Abnormal 99mTc-bone scan imaging must be confirmed by Computed Tomography (CT) Scan or Magnetic resonance Imaging (MRI)
  • Progressive disease following 1st line androgen deprivation therapy with LHRH (luteinizing hormone-releasing hormone) Agonists or surgical castration. Recommendations of Prostate Cancer Working Group 2 (PCWG2)
  • WHO (World health organization) performance status ≤ 2
  • Life expectancy > 12 weeks
  • Adequate bone marrow function (Absolute neutrophil count (ANC) 1500/μL; platelets 100,000/μL)
  • Castrate serum levels of testosterone (< 50 ng/dL)
  • Adequate renal function: calculated creatinine clearance > 40 mL/minute
  • Adequate hepatic function:

    • Bilirubin: total bilirubin 1.5 Upper limit of Normal (ULN)
    • Asparate aminotransferase (AST) and/or Alanine aminotransferase (ALT) ≤ 2.5 x ULN in the absence of liver metastases or ≤ 5 x ULN if liver metastases are present
  • Patients of reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 4 months following the last study treatment. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly
  • Before patient registration/randomization, written informed consent must be given according to ICH/GCP (International conference on Harmonization-Good Clinical Practices), and national/local regulations

Exclusion criteria

  • Cardiac function:

    • Screening calculated ejection fraction (Multi Gated Acquisition Scan (MUGA) scan, or by echocardiogram) must be ≥ 50%
    • No history of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias of Grade > 2 thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy) within 6 months prior to first dose of study drug
    • Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed
    • Absence of New York Heart Association Class III or IV heart failure
    • Absence of Electrocardiogram (ECG) abnormalities of: Q-wave infarction, unless identified 6 or more months prior to screening and QTc interval > 470 msec
    • No uncontrolled hypertension despite appropriate medical therapy defined as blood pressure >160/90 mmHg at 2 separate measurements no more than 60 minutes apart during the Screening visit
  • Prior radiotherapy but only for lymph nodes is allowed
  • Prior or concomitant therapy:

    • No intake of narcotic analgesia for bone pain
    • No prior treatment with non-steroidal antiandrogens, within 6 months prior to randomization
    • No anticancer therapy or treatment with another investigational agent within the last 4 weeks prior to randomization
    • No prior therapy with TAK-700, ketoconazole, abiraterone, aminoglutethimide or MDV3100
    • Patients taking bisphosphonates or denosumab are eligible if they have received a stable dose for 4 weeks or more prior to randomization. (These treatments may then be continued on study)
  • No known hypersensitivity to compounds related to TAK-700 or to TAK-700 excipients (refer to Investigator's brochure)
  • No known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of TAK-700, including difficulty swallowing tablets
  • No prior history of adrenal insufficiency
  • No prior history of malignancies other than prostate adenocarcinoma (except for basal cell or squamous cell carcinoma of the skin), or the patient has been free of malignancy for a period of 3 years prior to first dose of study drug
  • No known active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with participation in this study
  • No drug or alcohol abuse
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01658527

Layout table for location information
Onze Lieve Vrouw Ziekenhuis
Aals, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
AZ Groeninge Kortrijk - Campus Vercruysselaan
Kortrijck, Belgium
CHU Dinant Godinne - UCL Namur
Yvoir, Belgium
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Layout table for investigator information
Principal Investigator: Cora Sternberg San Camillo Forlanini Hospitals, Rome, Italy
Study Chair: Bertrand Tombal Cliniques Universitaires de St Luc, Brussels, Belgium

Layout table for additonal information
Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT01658527    
Other Study ID Numbers: EORTC-1211-GUCG-IG
2012-002122-67 ( EudraCT Number )
First Posted: August 7, 2012    Key Record Dates
Last Update Posted: June 10, 2016
Last Verified: June 2016
Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Androgen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents